Latin American collection network and banked specimens support broader patient representation and earlier-stage cancer research

拉丁美洲的样本采集网络和入库标本支持更广泛的患者代表性及早期癌症研究

CARLSBAD, Calif.

加利福尼亚州卡尔斯巴德

,

，

Oct. 29, 2026

2026年10月29日

/PRNewswire/ -- DCN Dx today announced its acquisition of BioSouthTech, Inc., a human biospecimen provider headquartered in the Miami area, with a collection network across Latin America, including South America, and access to specimens from the Caribbean. The acquisition expands DCN Dx's sample bank and patient access for drug and diagnostic research..

/美通社/ -- DCN Dx 今日宣布收购BioSouthTech, Inc.，这是一家总部位于迈阿密地区的人类生物样本提供商，其在拉丁美洲（包括南美洲）拥有采集网络，并可获取加勒比地区的生物样本。此次收购扩大了DCN Dx在药物和诊断研究方面的样本库及患者资源渠道。

Continue Reading

继续阅读

For developers of liquid biopsy assays, including multi-cancer early detection (MCED) and measurable residual disease (MRD) tests, specimens must reflect the disease stages and patient populations under study. The acquisition broadens DCN Dx's sourcing options for oncology, neurology, and autoimmune disease research..

对于液体活检检测（包括多癌种早期检测 [MCED] 和可测量残留病灶 [MRD] 检测）的开发者而言，样本必须反映所研究的疾病阶段和患者人群。此次收购拓宽了 DCN Dx 在肿瘤学、神经学和自身免疫性疾病研究方面的样本来源选择。

Access to a broader range of patient specimens helps diagnostic developers study how their tests perform across different populations. BioSouthTech expands that access through its banked specimens and Latin American collection network.

获得更广泛的患者样本有助于诊断产品开发者研究其检测方法在不同人群中的表现。BioSouthTech 通过其库存储备样本和拉丁美洲采集网络，扩大了这种样本获取渠道。

'We started our biospecimens business to give researchers better access to patients and support the collections their studies require,' said Charlie Mamrak, CEO of DCN Dx. 'Patient diversity was central to that decision. BioSouthTech gives our customers more ways to reach populations that their existing specimen sources may not represent.'.

DCN Dx 首席执行官 Charlie Mamrak 表示：“我们开展生物样本业务，旨在让研究人员能够更便捷地接触患者，并支持其研究所需的样本收集工作。患者多样性是这一决策的核心。BioSouthTech 为我们的客户提供了更多途径，以触达那些现有样本来源可能未能充分代表的人群。”

For developers of liquid biopsy assays, including multi-cancer early detection (MCED) and measurable residual disease (MRD) tests, specimens must reflect the disease stages and patient populations under study. The acquisition broadens DCN Dx's sourcing options for oncology, neurology, and autoimmune disease research..

对于液体活检检测（包括多癌早期检测 [MCED] 和可测量残留病灶 [MRD] 检测）的开发者而言，样本必须反映所研究的疾病阶段和患者人群。此次收购拓宽了 DCN Dx 在肿瘤学、神经学和自身免疫性疾病研究方面的样本来源选择。

'You can't develop a test for everyone on data from a few,' said Jim Boushell, senior vice president of biospecimens at DCN Dx. 'For two decades, I've watched technology evolve on data that doesn't quite reflect the patients those tests are meant to serve. We pursued BioSouthTech to give developers access to more diverse patient populations, including treatment-naive patients.

“你无法基于少数人的数据为所有人开发检测试剂，”DCN Dx生物样本高级副总裁吉姆·布谢尔表示。“二十年来，我目睹了技术在那些未能充分反映其目标患者群体的数据上不断演进。我们收购BioSouthTech，旨在让开发人员能够接触到更多样化的患者群体，包括初治患者。”

Patient diversity must be part of the evidence.'.

“患者多样性必须成为证据的一部分。”

Starting now, DCN Dx customers can request characterized tissue and matched sets off the shelf or stand-up prospective collections designed to their own protocol across oncology, neurology, and infectious disease. The network already reaches patients across a range of ancestries and regions, and new geographies and expanded cohorts are planned for early 2027..

即日起，DCN Dx 客户可以请求获取现成的特征化组织样本及匹配套装，或根据其在肿瘤学、神经学和传染病领域的自有方案设计的定制化前瞻性采集项目。该网络已覆盖具有不同祖先背景和地区的患者群体，并计划于 2027 年初拓展新的地理区域并扩大队列规模。

For more information about DCN Dx's biospecimen services, visit

如需了解更多关于 DCN Dx 生物样本服务的信息，请访问

dcndx.com/services/biospecimen

dcndx.com/services/biospecimen

.

。

About DCN Dx

关于 DCN Dx

For more than 20 years, DCN Dx has helped companies bring diagnostic tests to commercial success. The company combines an immunoassay CDMO, an IVD-dedicated CRO, and a biospecimen business offering banked specimens and direct collections. Its biospecimen team connects developers with diverse patient populations and specimens aligned to their study protocols and intended use.

二十多年来，DCN Dx 一直帮助企业将诊断测试推向商业成功。该公司整合了免疫分析合同开发与制造组织（CDMO）、专注于体外诊断（IVD）的合同研究组织（CRO），以及提供库藏样本和直接采集服务的生物样本业务。其生物样本团队将开发者与多样化的患者群体及与其研究方案和预期用途相匹配的样本连接起来。

Direct collections operate under IRB/IEC oversight, with standardized protocols, clinical and demographic data, and chain-of-custody documentation. DCN Dx is based in Carlsbad, California. Learn more at .

直接采集工作在机构审查委员会（IRB）/独立伦理委员会（IEC）的监督下进行，遵循标准化方案，并包含临床和人口统计学数据以及监管链文档。DCN Dx 总部位于加利福尼亚州卡尔斯巴德。了解更多请访问 。

dcndx.com

dcndx.com

.

。

MEDIA CONTACT

媒体联系人

Media Relations

媒体关系

647.335.4623

647.335.4623

[email protected]

[email protected]

DCNDx.com

DCNDx.com

SOURCE DCN Dx

源DCN Dx